Performance analysis of Nasus Pharma (NSRX)
Annual Return
Since Aug 13, 2025, NSRX has had an average annual return of -66.02%, underperforming the benchmark SPY, which returned +17.59% annual.
| 2026 | 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -67.11% | +10.91% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -37.26% | -16.56% | -53.65% | +21.63% | +24.44% | +4.15% | -14.00% | -67.11% | |||||
| 2025 | -1.82% | -17.90% | +16.98% | -10.02% | +30.71% | +10.91% |
Drawdown analysis of Nasus Pharma (NSRX)
The maximum drawdown for the NSRX was -78.04%, occurring on Mar 30, 2026. This drawdown has not yet recovered.
The current NSRX drawdown is -67.11%.
Since Aug 13, 2025 NSRX has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 2 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -78.04% | Dec 31, 2025 | 60 | Mar 30, 2026 | Ongoing | Ongoing | Ongoing |
| -30.95% | Aug 19, 2025 | 30 | Oct 1, 2025 | 63 | Dec 31, 2025 | 93 |
| -2.42% | Aug 13, 2025 | 1 | Aug 14, 2025 | 2 | Aug 18, 2025 | 3 |